Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1761 to 1770 of 2575 total matches.
Insect Venom Immunotherapy
The Medical Letter on Drugs and Therapeutics • Jul 09, 1993 (Issue 900)
generalized urticaria, bronchospasm,
laryngeal edema, hypotension and death. About 1% to 3% of adults ...
Systemic allergic reactions to insect stings can include generalized urticaria, bronchospasm, laryngeal edema, hypotension and death. About 1% to 3% of adults in the USA have had a systemic allergic reaction to an insect sting (RE Reisman, Med Clin North Am, 76:883, 1992; UR M ller, Monogr Allergy, 31:131, 1993).
Calcipotriene for Psoriasis
The Medical Letter on Drugs and Therapeutics • Aug 05, 1994 (Issue 928)
ointment with 0.1% betamethasone valerate ointment, a medium
potency corticosteroid (Medical Letter, 33 ...
Calcipotriene ointment 0.005% (calcipotriol; Dovonex - Westwood Squibb), a synthetic vitamin D 3 analog previously available in Europe and Canada, has now been approved by the US Food and Drug Administration (FDA) for treatment of moderate plaque psoriasis, the most common form of the disease.
Over-the-counter H2-Receptor Antagonists for Heartburn
The Medical Letter on Drugs and Therapeutics • Oct 27, 1995 (Issue 960)
ANTAGONISTS IN THE USA
Prescription dosage OTC dosage
1
OTC cost
2
Cimetidine − Tagamet HB (SK Beecham ...
Patients may be asking their physicians about use of histamine H2-receptor antagonists for treatment and prevention of heartburn. Cimetidine and famotidine have recently been released for over-the-counter sale and are being heavily advertised on television and in the print media.
Safety of Calcium-Channel Blockers
The Medical Letter on Drugs and Therapeutics • Feb 14, 1997 (Issue 994)
nifedipine, diltiazem or verapamil were 1.6 times more likely to have a myocardial infarction than patients ...
Reports of increased mortality associated with calcium-channel blockers have caused concerns among patients taking these drugs and their physicians.
Clopidogrel for Reduction of Atherosclerotic Events
The Medical Letter on Drugs and Therapeutics • Jun 05, 1998 (Issue 1028)
of
the carboxylic acid derivative reach a peak about 1 hour after a dose, and its half-life is about 8
hours ...
Clopidogrel bisulfate (Plavix - Bristol-Myers Squibb/Sanofi), a new thienopyridine antiplatelet agent similar to ticlopidine (Ticlid - Medical Letter, 34:65, 1992), has been approved by the US Food and Drug Administration (FDA) for secondary prevention of myocardial infarction, stroke and other vascular events.
New Monoclonal Antibodies to Prevent Transplant Rejection
The Medical Letter on Drugs and Therapeutics • Sep 25, 1998 (Issue 1036)
treated with cyclosporine, prednisone and azathioprine (Imuran), addition of daclizumab 1
mg/kg IV before ...
Basiliximab (Simulect - Novartis) and daclizumab (Zenapax - Roche), two mouse/human monoclonal antibodies that block the interleukin-2 (IL-2) receptor on Tlymphocytes, have been approved by the FDA for use in the prevention of acute renal transplant rejection. Both drugs are used with cyclosporine (Sandimmune; Neoral) and corticosteroids. An all-murine anti-CD3 monoclonal antibody, muromonab-CD3 (Orthoclone OKT3), has been available in the USA for many years for treatment of transplant rejection, and has also been used with some success for prophylaxis (MI Wilde and KL Goa, Drugs,...
Eflornithine Cream For Facial Hair Reduction
The Medical Letter on Drugs and Therapeutics • Oct 02, 2000 (Issue 1089)
of eflornithine from the 13.9% cream formulation is less than 1%. With twice-daily application, the peak serum ...
Eflornithine hydrochloride cream 13.9% (Vaniqa - Bristol-Myers Squibb) has been approved by the FDA for reduction of unwanted facial hair in women.
Direct-to-consumer Advertisements For Glucophage XR
The Medical Letter on Drugs and Therapeutics • Mar 19, 2001 (Issue 1100)
was slightly higher with the extended-release formulation (K Fujioka et al, Diabetes 2000; 49 suppl 1:A107 ...
Full-page newspaper advertisements addressed to patients with type 2 diabetes are promoting the convenience of "NEW once-a-day Glucophage XR (metformin HCl extended-release tablets),"and offering a coupon for a free 30-day supply in the month of March.
NSAID Alternatives
The Medical Letter on Drugs and Therapeutics • Jan 17, 2005 (Issue 1200)
their health care providers if
they should continue, and some may be asking for alternatives.
1,2
For most ...
Patients taking nonsteroidal anti-inflammatory drugs (NSAIDs) may be asking their health care providers if they should continue, and some may be asking for alternatives. For most patients taking nonspecific NSAIDs, it would be reasonable to continue. For those who are taking the COX-2 selective celecoxib (Celebrex) because they cannot tolerate the gastrointestinal (GI) effects of nonspecific NSAIDs, it seems reasonable to continue at doses no higher than 100 mg b.i.d. or 200 mg once daily; at these dosages cardiovascular risk has been no higher than with placebo. All NSAIDs, including COX-2...
In Brief: Propylthiouracil for Hyperthyroidism
The Medical Letter on Drugs and Therapeutics • Jul 27, 2009 (Issue 1317)
The thionamides propylthiouracil and methimazole are
both used to treat hyperthyroidism.
1
Propylthiouracil ...
The thionamides propylthiouracil and methimazole are both used to treat hyperthyroidism.1 Propylthiouracil causes severe hepatic toxicity or hepatic failure in about 0.1% of adults and children.2,3 It is the third leading cause of liver transplants due to drug toxicity (acetaminophen and isoniazid are the first two). Methimazole may cause less serious hepatic toxicity; reversible cholestatic jaundice has been reported. There is generally no good reason to continue to use propylthiouracil, with 2 possible exceptions. First, propylthiouracil may be preferred for treatment of life-threatening...